II. Indications (age 10 years old or older)

  1. Serotype B Meningococcal Meningitis exposure
  2. Asplenia
  3. Sickle Cell Disease
  4. Specific immune deficiency

III. Mechanism

  1. Covers only Serotype B Meningococcus
    1. Accounts for one third of meningococcal cases
    2. Serotype B outbreaks are most common in infants and college students
  2. Contrast with Menactra, Menveo and Menomune which cover serotypes A, C, W and Y
    1. Indicated for all U.S. children as part of the Primary Series

IV. Preparations (FDA approved in 2014)

  1. Trumenba (3 dose series at 0, 2 and 6 months)
  2. Bexero (2 dose series, one month or more between doses)

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window